RAC 3.01% $1.45 race oncology ltd

Ann: Zantrene data published in Cancer Research Journal, page-5

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 964 Posts.
    lightbulb Created with Sketch. 555
    Always good to see Zantrene's anti-cancer, FTO inhibition potency validated independently, and published especially in Highly Rated international journals.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.